109 related articles for article (PubMed ID: 31603327)
1. Metabonomic Investigation of Biological Effects of a New Vessel Target Protein tTF-pHLIP in a Mouse Model.
Ding L; Zhang C; Liu Z; Huang Q; Zhang Y; Li S; Nie G; Tang H; Wang Y
J Proteome Res; 2020 Jan; 19(1):238-247. PubMed ID: 31603327
[TBL] [Abstract][Full Text] [Related]
2. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth.
Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G
Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637
[TBL] [Abstract][Full Text] [Related]
3. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
4. Tissue-factor fusion proteins induce occlusion of tumor vessels.
Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.
Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL
Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833
[TBL] [Abstract][Full Text] [Related]
6. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
[TBL] [Abstract][Full Text] [Related]
7. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
Huang ZJ; Luo Q; Yan JH; Wang SY
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.
Svoronos AA; Bahal R; Pereira MC; Barrera FN; Deacon JC; Bosenberg M; DiMaio D; Glazer PM; Engelman DM
Mol Pharm; 2020 Feb; 17(2):461-471. PubMed ID: 31855437
[TBL] [Abstract][Full Text] [Related]
10. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice].
Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Targeted Delivery of IL-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy.
Chu T; Cao B; Wang P; Li B; Ren J; Nie G; Wei J; Li S
Bioconjug Chem; 2023 Oct; 34(10):1894-1901. PubMed ID: 37787935
[TBL] [Abstract][Full Text] [Related]
12. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
Yu M; Chen Y; Wang Z; Ding X
Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579
[TBL] [Abstract][Full Text] [Related]
13. Fusion protein tTF-EG3287 induces occlusion of tumor vessels and impairs tumor growth in human colon caner.
Qiu GQ; Xie X; Zhao B; Xu LZ; Chen YQ
Neoplasma; 2019 Mar; 66(2):252-260. PubMed ID: 30569722
[TBL] [Abstract][Full Text] [Related]
14. pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent.
Wei Y; Liao R; Mahmood AA; Xu H; Zhou Q
Acta Biomater; 2017 Jun; 55():194-203. PubMed ID: 28363789
[TBL] [Abstract][Full Text] [Related]
15. [Expression and characterization of fusion protein tTF/SA as a universal effector for targeting blood coagulation].
Wang Z; Yan JH; Wang JP; Xie LY; Wu N
Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):218-22. PubMed ID: 17460891
[TBL] [Abstract][Full Text] [Related]
16. pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.
Zhao Z; Li C; Song B; Sun J; Fu X; Yang F; Wang H; Yan B
Biochem Biophys Res Commun; 2018 Sep; 503(3):1761-1767. PubMed ID: 30131247
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
[TBL] [Abstract][Full Text] [Related]
18. [Gene expression and activities analysis of a new fusion protein (RGD) 3/tTF].
Yan JH; Yang GW; Wang JP; Wu N; Zhuang GH
Sheng Wu Gong Cheng Xue Bao; 2007 May; 23(3):409-12. PubMed ID: 17577984
[TBL] [Abstract][Full Text] [Related]
19. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
[TBL] [Abstract][Full Text] [Related]
20. pH-dependent thermodynamic intermediates of pHLIP membrane insertion determined by solid-state NMR spectroscopy.
Otieno SA; Hanz SZ; Chakravorty B; Zhang A; Klees LM; An M; Qiang W
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12194-12199. PubMed ID: 30442664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
